title: Effective immuno-targeting of the IDH1 mutation R132H in a murine model of intracranial glioma.
abstract: The R132H mutation of cytosolic isocitrate dehydrogenase (IDH1) is present in the majority of low grade gliomas.Immunotherapy in these tumors has an interesting, still unexploited, therapeutic potential, as they are less immunosuppressive than glioblastomas. Using site-directed mutagenesis we introduced the R132H mutation into the murine glioma cell line GL261,creating mIDH1-GL261. Presence of the mutation was confirmed by immunoblotting and production of the oncometabolite 2-hydroxyglutarate (2HG), demonstrated by mass spectrometry (LC-MS/MS) performed on cell supernatant. In vitro mIDH1-GL261 had different morphology but similar growth rate than parental GL261 (p-GL261). After intracranial injection, MRI suggested that the initial growth rate was slower in mIDH1-GL261 than p-GL261 gliomas but overall survival was similar. mIDH1-GL261 gliomas showed evidence of R132H expression and of intratumoral 2HG production (evaluated by MRS and LC-MS/MS). Immunizations were performed nine days after intracranial implantation of mIDH1- or p-GL261 cells by three subcutaneous injections of five different peptides encompassing the IDH1 mutation site, all emulsified with Montanide ISA-51, in association with GM-CSF. Control mice were injected with four ovalbumin peptides or vehicle. Mice with mIDH1-GL261 but not p-GL261 gliomas treated with mIDH1 peptides survived longer than controls; 25% of them were cured. Immunized mice showed higher amounts of peripheral CD8+ T cells, higher production of IFN-γ, and evidence of anti-mIDH1 antibodies.Immunizations led to intratumoral up-regulation of IFN-γ, granzyme-b and perforin-1 and down-regulation of TGF-β2 and IL-10. These results support the translational potential of immunotherapeutic targeting of gliomas carrying IDH1 mutations.
authors: Serena
authors: S
authors: Pellegatta
authors: Lorella
authors: L
authors: Valletta
authors: Cristina
authors: C
authors: Corbetta
authors: Monica
authors: M
authors: Patanè
authors: Ileana
authors: I
authors: Zucca
authors: Federico
authors: F
authors: Riccardi Sirtori
authors: Maria Grazia
authors: MG
authors: Bruzzone
authors: Gianpaolo
authors: G
authors: Fogliatto
authors: Antonella
authors: A
authors: Isacchi
authors: Bianca
authors: B
authors: Pollo
authors: Gaetano
authors: G
authors: Finocchiaro
mesh_terms: D000818:Animals; D014408:Biomarkers, Tumor / Q000235:genetics / Q000276:immunology; D001932:Brain Neoplasms / Q000235:genetics* / Q000276:immunology*; D045744:Cell Line, Tumor; D004195:Disease Models, Animal; D015536:Down-Regulation; D008401:Gas Chromatography-Mass Spectrometry; D005910:Glioma / Q000235:genetics* / Q000276:immunology* / Q000628:therapy; D005977:Glutarates / Q000378:metabolism; D053804:Granzymes / Q000378:metabolism; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000378:metabolism; D016753:Interleukin-10 / Q000378:metabolism; D007521:Isocitrate Dehydrogenase / Q000235:genetics* / Q000276:immunology; D051379:Mice; D008810:Mice, Inbred C57BL; D009154:Mutation; D054353:Perforin / Q000378:metabolism; D053781:Transforming Growth Factor beta2 / Q000378:metabolism
chemical_list: D014408:Biomarkers, Tumor; D005977:Glutarates; D053781:Transforming Growth Factor beta2; D054353:Perforin; D016753:Interleukin-10; C019417:alpha-hydroxyglutarate; D007371:Interferon-gamma; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human; D053804:Granzymes